Abstract 396P
Background
Despite the many cervical cancer prevention interventions recommended and supported by WHO and partners of low- and middle-income countries; the burden of cancer is high in Uganda and the East African region. Little is known about factors associated with participating in screening at a primary health facility (PHF) and referral to a high-level facility.
Methods
A cross-sectional study was conducted from February to March 2018 at Uganda Cancer Institute (UCI) among women visiting for cervical cancer screening. A structured questionnaire was used. Women suspected for cervical cancer and provided consent were enrolled and administered the questionnaire. Ethics review and approval was obtained from UCI research and ethics committee. A Stata version 14.1 software was used and Chi-square tests and multivariate logistic regression analyses performed.
Results
Among 522 women enrolled, only 3.26% (17) had a formal referral note and 62.64% (327) had participated in cervical cancer screening before visiting UCI. There was a 17.65% false-positive rate among the referred women suspected with cervical cancer. 67.18% (131) among those who had never screened reported personal beliefs as a factor deterring their participation. Most women were aged between 35-44 years old (ORs=2.45, 95% CI = 1.61-3.72) who were divorced/widowed (ORs=1.89, 95% CI = 1.07-3.34) and drinking alcohol (ORs=0.51, 95% CI = 0.31-0.83). Among the referred women, 17.65% delayed to honour a referral request for more than a month because of socio-economic challenges. Factors such as high education level (ORs=0.11, 95% CI = 0.02-0.48) and confirmatory tests (ORs=6.10, 95% CI = 1.93-19.31) done at UCI were associated with referrals.
Conclusions
The present study identified factors associated with participation in screening at a PHF and referral to a high-level facility, which provides better understanding of lost follow-up after screening. Awareness in high risk groups, increase of screening facilities and integration of screening services with existing health programs is necessary.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Uganda Cancer Institute-African Development Bank capacity building fund.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
313P - Immunotherapy application for advanced cancers: One institution experiences since 2016 to 2019
Presenter: Jo Pai Chen
Session: Poster display session
Resources:
Abstract
314P - An EGF motif of Del1 inhibits efficient angiogenesis and suppresses tumour growth in vivo
Presenter: Hisataka Kitano
Session: Poster display session
Resources:
Abstract
315P - Inhibition of JAK1 sensitizes human head and neck cancer cells to cetuximab
Presenter: James Bonner
Session: Poster display session
Resources:
Abstract
316TiP - Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study
Presenter: Ezra Cohen
Session: Poster display session
Resources:
Abstract
322P - Three-year overall survival update from the PACIFIC trial
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract
323P - Novel tumour mutation score versus tumour mutation burden in predicting survival after immunotherapy in pan-cancer from MSK-IMPACT cohort
Presenter: Yuan Li
Session: Poster display session
Resources:
Abstract
324P - A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy
Presenter: Tsu Yi Chao
Session: Poster display session
Resources:
Abstract
325P - Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma
Presenter: Lawrence Wong
Session: Poster display session
Resources:
Abstract
326P - Autologous V gamma 9 V delta 2 T cell therapy to target Epstein Barr Virus (EBV)-related malignancies
Presenter: Esdy Rozali
Session: Poster display session
Resources:
Abstract
327P - Neoantigen profile of hepatocellular carcinoma reveals its correlation with tumour progression and clonal evolution
Presenter: Xiaolong Liu
Session: Poster display session
Resources:
Abstract